Cosequin Equine Powder
€144.00
Why Cosequin Equine Powder?
-
- Cosequin Equine Powder contains all 3 essentials for joint fluid and cartilage repair for use in treating stiff sore horses associated with arthritis or navicular disease.
- Cosequin is an exclusive formula of three important ingredients: TRH122®* low molecular weight chondroitin sulfate, FCHG49®* glucosamine hydrochloride, and manganese ascorbate.
- These ingredients have been scientifically formulated to support and maintain the health of your horse’s joints.
- Published studies have shown that the specific combination of ingredients in Cosequin helps to maintain the structure of the cartilage while inhibiting the enzymes that break down cartilage.
- Cosequin is the only glucosamine/chondroitin sulfate brand that has been shown safe, bioavailable and effective in horses in published studies.1-5
* Cosequin® contains FCHG49® Glucosamine Hydrochloride and TRH122® Low Molecular Weight Sodium Chondroitin Sulfate, Nutramax Laboratories® exclusive veterinary researched specifications.
Instructions for use for Cosequin Equine Powder
| Body Weight | Initital Period 2-4 Weeks |
Economical Long-Term Administration |
|---|---|---|
| Under 600 lbs | 2 scoops in AM & 2 scoops in PM |
1 scoop daily |
| 600 – 1200 lbs | 3 scoops in AM & 3 scoops in PM |
1-2 scoops daily |
| Over 1200 lbs | 4 scoops in AM & 4 scoops in PM |
2 scoops daily |
This chart should be used for guidance. Detailed instructions are contained in the package insert.
Each 3.3 Grams (1 Level Scoop) Contain
| Manganese* minimum | 16 mg |
| Glucosamine Hydrochloride† minimum | 1,800 mg |
| Sodium Chondroitin Sulfate† minimum | 600 mg‡ |
*From manganese ascorbate.
†Cosequin® contains FCHG49® Glucosamine and TRH122® Sodium Chondroitin Sulfate, Nutramax Laboratories® proprietary veterinary researched specifications.
‡Reported on a hydrous basis.
References
1. Hanson RR, Smalley LR, Huff GK, et.al. Equine Practice 19(9):16-22, 1997.
2. Hanson RR, Brawner WR, Blaik MA, et al. Veterinary Therapeutics 2(2):148-159, 2001.
3. Kirker-Head CA, Kirker-Head RF. Veterinary Therapeutics 2(4):345-353, 2001.
4. Du J, White N, Eddington, ND. Biopharmaceutics and Drug Disposition 25(3):109-116, 2004.
5. Orth MW, Peters TL, Hawkins JN. Equine Veterinary Journal Suppl. (34):224-229, 2002.
Reviews
There are no reviews yet.